Paia Biotech

Executive Summary

Paia Biotech is a German biotechnology company specializing in high-throughput analytical solutions for biologics characterization. Founded in 2018 and headquartered in Munich (with operations in Cologne), the company offers ready-to-use 384-well plate-based kits for measuring critical quality attributes such as titer, glycan profiles, and aggregation. These assays are essential for monoclonal antibody and other biologic drug development, quality control, and process optimization. Paia’s product line targets the growing demand for efficient, standardized analytical tools in the biopharmaceutical industry. As a private company, Paia Biotech operates in the competitive landscape of analytical service and kit providers. Its focus on automation-ready, high-density plate formats positions it well for integration into bioprocessing workflows. The company's early-stage nature and lack of disclosed funding or valuation suggest it is still in a growth phase, likely seeking partnerships or further investment. The increasing complexity of biologics and regulatory emphasis on thorough characterization bode well for demand. However, limited public information constrains assessment of financial health and competitive moat.